Market research
CXT.F Carmat SA
F EUR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.02
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- FR0010907956
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.02
About
About Carmat SA
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CXT.F discussion.
5 years, 4 months ago
Carmat SA is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Carmat SA's total revenue sank by 0.0% to $346K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.5% to $-13M since the same quarter in the previous year.
Based on the above factors, Carmat SA gets an overall score of 1/5.